Detection of K14 in Bladder Cancer With a Non Invasive Technique
Terminated
- Conditions
- Bladder Cancer
- Registration Number
- NCT02027649
- Lead Sponsor
- Corporacion Parc Tauli
- Brief Summary
By an invasive technique keratin 14 has been identified as a prognostic factor in bladder cancer. This study aims to analyze whether through a non-invasive technique keratin 14 can be used as a diagnostic and prognostic marker for this cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
- Bladder cancer
Exclusion Criteria
- Inability to sign the informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Keratin 14 At the time of study entry
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link keratin 14 expression to bladder cancer prognosis and diagnosis in urothelial cells?
How does non-invasive K14 detection compare to standard-of-care methods like urine cytology for bladder cancer diagnosis?
Which biomarkers in urothelial cells predict response to non-invasive K14-based diagnostic approaches in bladder cancer?
What are the potential adverse events associated with non-invasive K14 testing in bladder cancer patients?
Are there combination therapies involving K14-targeted diagnostics for bladder cancer management, as explored in NCT02027649?
Trial Locations
- Locations (1)
Corporació Sanitària i Universitària Parc Taulí
🇪🇸Sabadell, Barcelona, Spain